> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Prothena Research Spending Falls To $8.4 Million — Quarterly Revenue Also Shrinks
- URL: https://www.bullished.co/prothena-research-spending-falls-to-8-4-million-quarterly-revenue-also-shrinks-ae6f8cf8/
- Published: 2026-11-06T15:21:51.000Z
- Updated: 2026-11-06T15:21:51.000Z
- Description: The biotech kept its cash-use forecast unchanged and expects an Alzheimer's trial readout in the first half of 2027.
- Author: Matteo Parrino
- Tags: SEC Filings, PRTA, Industry: Healthcare

[Prothena](https://www.bullished.co/tag/prta/), which develops antibody medicines for diseases caused by misfolded proteins, cut third-quarter research spending to $8.4 million from $28.9 million a year earlier and reported a smaller loss Thursday. Results accompanying its [SEC filing](https://www.sec.gov/Archives/edgar/data/0001559053/000155905326000030/prta-20261105.htm?ref=bullished.co) put the loss at $16.5 million, versus $36.5 million, even as revenue declined.

## Lower Costs, Lower Revenue

Quarterly revenue fell to [$0.6 million](https://www.sec.gov/Archives/edgar/data/0001559053/000155905326000030/exhibit991q32026earningsre.htm?ref=bullished.co) from $2.4 million a year earlier. The loss per share narrowed to $0.32 from $0.68.

Prothena attributed the research-spending decline to reduced trial, staffing and consulting costs. Administrative spending also fell, to $10.6 million from $13.2 million, with personnel and consulting expenses again accounting for the reduction.

The first nine months tell a different revenue story: a $50.0 million milestone payment from Novo tied to coramitug's ongoing late-stage trial helped lift revenue to $52.7 million from $9.7 million. Bristol Myers Squibb collaboration revenue also contributed. The nine-month loss narrowed to $2.4 million, or $0.05 per share, from $222.5 million, or $4.13 per share.

Research spending for that period was $29.9 million, versus $120.3 million, while administrative expenses were $34.2 million, versus $46.7 million. Restructuring produced a $1.4 million credit, compared with $33.1 million in expenses a year earlier.

## Cash Forecast Leaves Buybacks Separate

Prothena ended the quarter with [$272.2 million](https://www.sec.gov/Archives/edgar/data/0001559053/000155905326000030/exhibit991q32026earningsre.htm?ref=bullished.co) in cash, cash equivalents and restricted cash, and no debt. Operating and investing activities used $12.0 million during the quarter and $8.9 million across the first nine months.

Management retained its 2026 operating-and-investing cash-use forecast of $18 million to $23 million and projected approximately $259 million in year-end cash at the midpoint. The forecast excludes additional buybacks. Its expected annual loss of $25 million to $30 million includes an estimated $26 million in non-cash stock-based pay.

Buybacks consumed $26.6 million, excluding commissions and expenses, for 2,745,380 shares in the first nine months. That included 501,492 shares in the third quarter. The program permits up to $100.0 million in purchases and expires December 31, 2026.

PRTA shares rose about 2% to $8.05 in Friday trading.

## Partnered Trials Carry The Milestones

Prothena's business relies on drug-company partnerships alongside its own research programs. Roche is testing prasinezumab for Parkinson's disease in a late-stage trial, and Novo is testing coramitug for ATTR amyloidosis with cardiomyopathy, a heart-affecting amyloid disease. Both trials have primary completion expected in 2029.

Gene Kinney, Prothena's president and chief executive officer, said those partnerships have generated $650 million in upfront payments, milestones and equity payments. They could bring “over $2.25 billion in [additional milestone payments](https://www.sec.gov/Archives/edgar/data/0001559053/000155905326000030/exhibit991q32026earningsre.htm?ref=bullished.co), plus potential royalties,” he said.

Novo also presented a retrospective analysis of its mid-stage coramitug trial: at week 52, pooled treatment groups showed an approximately 8% decline in an inflammatory marker, compared with an approximately 33% increase in the placebo group. Coramitug and Bristol Myers Squibb's Alzheimer's candidate moponetug have FDA Fast Track designations.

Prothena's wholly owned preclinical work includes PRX012-TfR for Alzheimer's disease and TDP-43 CYTOPE, which targets disease pathways inside cells associated with ALS and other disorders. The company is also exploring CYTOPE through industry research collaborations over the next 12 to 24 months.

The next expected partnered trial readout is Bristol Myers Squibb's mid-stage moponetug study in approximately 310 patients with early Alzheimer's disease, with results anticipated in the first half of 2027.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — PROTHENA CORP PUBLIC LTD CO (PRTA)](https://www.sec.gov/Archives/edgar/data/0001559053/000155905326000030/prta-20261105.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit exhibit991q32026earningsre.htm — PROTHENA CORP PUBLIC LTD CO 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001559053/000155905326000030/exhibit991q32026earningsre.htm?ref=bullished.co) — SEC EDGAR
- [Prothena Reports Third Quarter 2026 Financial Results and Business Highlights](https://www.businesswire.com/news/home/20261105178540/en/Prothena-Reports-Third-Quarter-2026-Financial-Results-and-Business-Highlights?ref=bullished.co) — businesswire.com

### More on Prothena

- [Prothena's Chief Development Officer Resigns To Join A Strategic Partner, 8-K Shows](https://www.bullished.co/prothenas-chief-development-officer-resigns-to-join-a-strategic-partner-8-k-shows-23324231/)

[All Prothena (PRTA) coverage →](https://www.bullished.co/tag/prta/)